Source:http://linkedlifedata.com/resource/pubmed/id/11975760
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2002-4-26
|
| pubmed:abstractText |
Cytokine-immunoglobulin (Ig)-fusion proteins have attracted increasing interest as antitumour agents. Here, we have investigated the antimetastatic and antitumour responses elicited in vivo by mammary adenocarcinoma cells (TS/A) engineered to secrete interleukin (IL)-2-IgG fusion proteins. TS/A cells were transfected with DNA coding for IL-2-IgG2b, IgG2b or IL-2, and injected subcutaneously into syngeneic mice. Animals injected with TS/A-IL-2 or TS/A-IL-2-IgG2b both efficiently rejected tumours, whereas treatment with parental cells or TS/A-IgG2b was lethal. Interestingly, only mice vaccinated with IL-2-IgG2b fusion protein-secreting cells showed a long-lasting protective immunity against a later challenge with parental tumour cells. Moreover, the metastatic potential of TS/A-IL-2-IgG2b-transfected cells was dramatically decreased compared with TS/A-IL-2-cells, with a virtual absence of lung metastases after intravenous injection. Adenocarcinomas secreting IL-2-IgG2b exhibited a more prominent, early and persistent infiltration of CD4+, CD8+ and natural killer (NK) cells than TS/A-IL-2 cells. Therefore, upon transfection into adenocarcinoma cells, the IgG2b part of IL-2 fusion protein exerts intriguing added antitumour properties over IL-2 alone, thus contributing to a long-lasting tumour immunity, probably by the recruitment of specific immune effector cells. These findings suggest a promising new oncotherapeutic strategy for poorly immunogenic tumours: vaccination with tumour cells engineered to secrete IL-2-IgG2b fusion protein.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0300-9475
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
55
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
484-92
|
| pubmed:dateRevised |
2011-3-15
|
| pubmed:meshHeading |
pubmed-meshheading:11975760-Adenocarcinoma,
pubmed-meshheading:11975760-Animals,
pubmed-meshheading:11975760-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11975760-CD8-Positive T-Lymphocytes,
pubmed-meshheading:11975760-Female,
pubmed-meshheading:11975760-Growth Inhibitors,
pubmed-meshheading:11975760-Immunoglobulin G,
pubmed-meshheading:11975760-Immunohistochemistry,
pubmed-meshheading:11975760-Immunotherapy,
pubmed-meshheading:11975760-Interleukin-2,
pubmed-meshheading:11975760-Killer Cells, Natural,
pubmed-meshheading:11975760-Lung Neoplasms,
pubmed-meshheading:11975760-Mammary Neoplasms, Experimental,
pubmed-meshheading:11975760-Mice,
pubmed-meshheading:11975760-Mice, Inbred BALB C,
pubmed-meshheading:11975760-Recombinant Fusion Proteins,
pubmed-meshheading:11975760-Transfection,
pubmed-meshheading:11975760-Tumor Cells, Cultured
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein.
|
| pubmed:affiliation |
Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany.
|
| pubmed:publicationType |
Journal Article,
Retracted Publication,
Research Support, Non-U.S. Gov't
|